Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 4/20 | 0.55 |
| ▸ | GPR132 | Q9UNW8 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | CCKAR | P32238 | 1/20 | 0.48 |
| ▸ | CCKBR | P32239 | 1/20 | 0.48 |
| ▸ | KIFC1 | Q9BW19 | 1/20 | 0.48 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.47 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23461004 | 0.94 | GPR34 (0.56) | ELANEGPR132PPARGKIFC1CXCR2 | |
| SCHEMBL23460860 | 0.94 | ELANE (0.50) | ELANEGPR132MEN1KMT2APPARG | |
| SCHEMBL25194649 | 0.94 | PTPN1 (0.57) | ELANEGPR132MEN1KMT2APPARG | |
| SCHEMBL25194648 | 0.94 | PTPN1 (0.57) | ELANEGPR132MEN1KMT2APPARG | |
| SCHEMBL23460863 | 0.94 | ELANE (0.50) | ELANEGPR132MEN1KMT2APPARG | |
| SCHEMBL23461000 | 0.94 | GPR34 (0.56) | ELANEGPR132PPARGKIFC1CXCR2 | |
| SCHEMBL23460938 | 0.91 | CXCR2 (0.52) | ELANEGPR132MEN1KMT2APPARG | |
| SCHEMBL23461059 | 0.91 | CXCR2 (0.61) | ELANEGPR132PPARGKIFC1CXCR2 | |
| SCHEMBL23461061 | 0.91 | CXCR2 (0.61) | ELANEGPR132PPARGKIFC1CXCR2 | |
| SCHEMBL23460817 | 0.91 | GPR34 (0.51) | ELANEGPR132MEN1KMT2APPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159438-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-25 | — | — | US | disclosed |
| US-20230159438-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159438-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | CFTR, AADAC, ARSA | ELANE 49/4885GPR132 750/4885MEN1 4477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.